Conclusion: Normally, internationalresearches about directmedicalcostoftreatingthe lung cancer investigate totalcosts from the firstdiagnosisuntilseveral yearslater.
Under HSTP the aim is to achieve structural efficiencies in three areas production, direct materials costs, and indirect costs, where current totalcosts are JPY 9 trillion (USD 113 billion).